Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

WeightWatchers has appointed Dr. Kim Boyd as chief medical officer and announced a new program focused on helping women ...

Novo Nordisk confirmed on Monday it would cease its agreement with U.S. telehealth firm Hims & Hers Health regarding its Wegovy weight-loss drug, prompting a 31% dip in Hims shares during morning ...

Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more weight in a shorter time frame compared to Novo Nordisk's Wegovy. According ...

The compounded versions cost consumers considerably less than the brand-name GLP-1 drugs. Novo Nordisk said it had been working with telehealth companies to help transition patients from the ...

Novo Nordisk said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy. Novo ...

Hims & Hers Health Inc.’s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...

In April, Novo Nordisk began partnering with multiple telehealth companies, including Hims & Hers, to expand access to Wegovy after the shortage ended, CNBC reported. Under FDA regulations, compounded ...

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.